APTO — Aptose Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $19.31m
- $10.06m
Annual cashflow statement for Aptose Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.3 | -55.2 | -65.4 | -41.8 | -51.2 |
| Depreciation | |||||
| Non-Cash Items | 3.15 | 22 | 20.9 | 5.61 | 4.12 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.42 | -0.799 | 0.961 | 3.77 | 2.4 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -21.6 | -33.9 | -43.3 | -32.3 | -44.6 |
| Capital Expenditures | -0.102 | -0.079 | -0.212 | -0.024 | -0.029 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -17.3 | 12.7 | -35 | 30.1 | 9.99 |
| Change in Net Investments | |||||
| Cash from Investing Activities | -17.4 | 12.6 | -35.2 | 30.1 | 9.96 |
| Financing Cash Flow Items | -0.437 | -0.168 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 103 | 58.8 | 0.226 | 0.116 | 6.91 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 64.5 | 37.6 | -78.3 | -2.14 | -27.7 |